Department of Medicine, Tri-Service General Hospital, Taipei 114, Taiwan.
Division of Hematology/Oncology, Department of Internal Medicine, National Defense Medical Center, Taipei 114, Taiwan.
World J Gastroenterol. 2024 Jun 7;30(21):2748-2750. doi: 10.3748/wjg.v30.i21.2748.
In this editorial, we offer a summary of the risk associated with hepatitis B reactivation (HBVr) in the setting of both solid and hematologic malignancies treated with Bruton tyrosine kinase (BTK) inhibitors, with insights derived from current studies. Furthermore, we emphasize the critical need for a framework regarding robust risk evaluation in patients undergoing such treatments. This framework is essential for identifying those at increased risk of HBVr, enabling healthcare providers to implement proactive measures to prevent reactivation and ensure the safe administration of BTK inhibitor therapy.
在这篇社论中，我们总结了在接受布鲁顿酪氨酸激酶（BTK）抑制剂治疗的实体瘤和血液系统恶性肿瘤患者中，乙型肝炎病毒再激活（HBVr）的风险，并从当前研究中获得了一些见解。此外，我们强调了在接受此类治疗的患者中建立一个关于风险评估的框架的重要性。该框架对于识别那些 HBVr 风险增加的患者至关重要，使医疗保健提供者能够采取主动措施来预防再激活并确保 BTK 抑制剂治疗的安全管理。
